Developer docs
API playgroundTry for free, no card

Search company profiles

Cessatech

Full company profile

uuid0002csm

Namestring
Cessatech
Legal namestring
Cessatech A/S
Websiteurl
cessatech.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Cessatech A/S is a Danish pivotal-stage paediatric biotech company founded in 2020 as a spinout from Rigshospitalet, Copenhagen University Hospital. The company develops first-in-class specialty hospital medicines targeting acute and emergency care needs in children aged 1-17. Its portfolio addresses a documented under-treatment of pediatric pain where IV access is often painful or infeasible and where many current regimens rely on off-label use.

The lead asset, CT001 (Napatrin), is a fixed-dose combination nasal spray containing ketamine and sufentanil, leveraging a synergistic analgesic effect that enables approximately 30% opioid reduction without loss of efficacy. Pivotal trial 0205 enrolled 220 adult patients and final pediatric safety Study 0202 enrolled over 150 children, with top-line results showing 54% responder rate at 15 minutes and 88% at 30 minutes. The pipeline also includes CT002 (intranasal dexmedetomidine for procedural sedation, with EMA-approved PIP), CT003 (topical anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for post-anaesthesia emergence delirium, developed in collaboration with Rigshospitalet). CT001 has received a positive MDR opinion and an EMA PUMA-based MAA was submitted in August 2025.

Cessatech operates a capital-efficient, partnership-driven commercial model with a lean team of fewer than 10 employees. In the US, Ventis Pharma holds exclusive commercialization rights and STAQ Pharma is the manufacturing partner, with 50/50 cost and profit sharing and a projected $200-400M market opportunity within 5 years. In Europe and ex-US markets, Proveca Ltd holds exclusive commercialization rights and is the marketing authorization holder, with Cessatech receiving double-digit royalties plus upfront and milestone payments. The company is publicly listed on the Spotlight Stock Market under the ticker CESSA, having raised approximately DKK 78 million cumulatively since its oversubscribed 2020 IPO.

Short descriptiontext

Cessatech is a Danish pivotal-stage paediatric biotech company developing first-in-class fixed-dose nasal spray and injectable medicines for acute and emergency care in children. It licenses lead asset CT001 through exclusive US (Ventis/STAQ) and Europe/ex-US (Proveca) commercial partnerships ahead of near-term launches.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pediatric pharmaceuticals, nasal spray medicines, acute pain management, fixed-dose combinations, specialty hospital medicines
Industry2 codes
PRIMARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAM
First Aid & Wound Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pediatric Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales - US Market
TypeTransaction Fee
Description

Revenue from CT001 sales in the US market through the partnership with Ventis Pharma and STAQ Pharma. Both parties share development costs and net profits equally (50/50). Expected to generate revenue from 2024, though timeline has been extended due to manufacturing validation requirements.

in.marketscreener.com
2Licensing Royalties - Europe/Ex-US
TypeLicensing Royalties
Description

Double-digit royalties to Cessatech on net sales in the licensed territory through the exclusive agreement with Proveca for worldwide commercialization excluding US. Proveca is the marketing authorization holder for Europe.

cessatech.com
3Upfront and Milestone Payments
TypeLicensing Royalties
Description

Upfront payment upon signature of the Proveca agreement plus potential milestone payments as regulatory and commercial milestones are achieved.

cessatech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cessatech develops first-in-class specialty hospital medicines for children, focused on acute and emergency care. The lead product CT001 (Napatrin) is a fixed-dose combination analgesic nasal spray of ketamine and sufentanil for children aged 1-17 years experiencing acute pain. The pipeline also includes CT002 (procedural sedation nasal spray), CT003 (sterile local anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for emergence delirium).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 54% of patients reported pain relief (pain score ≤4/10) after 15 minutes
+4 more records
Product overview1 text field

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children. The company's portfolio includes four pipeline products: CT001 (Napatrin) is the lead product, a nasal spray for acute pain in children aged 1-17; CT002 is a nasal spray for procedural sedation during MRI scans; CT003 is a topical anaesthetic gel for laceration repair; and CT004 is an intravenous melatonin formulation for emergence delirium. The company operates a capital-efficient, partnership-driven model with lead product CT001 advancing toward near-term commercialization in both US and European markets.

Product and service4 records
1CT001 (Napatrin)
CategoryPediatric Pharmaceuticals
Description

Fixed-dose analgesic nasal spray combining ketamine and sufentanil for acute pain relief in children aged 1-17 years. Non-invasive, needle-free formulation with fast onset, designed for children experiencing acute pain or pain related to medical procedures.

2CT002
CategoryPediatric Pharmaceuticals
Description

Non-invasive nasal spray containing dexmedetomidine for conscious sedation of children undergoing medical procedures such as MRI scans and diagnostic imaging.

3CT003
CategoryPediatric Pharmaceuticals
Description

Topical anaesthetic gel for paediatric laceration repair. Ready-to-use, sterile, needle-free local anaesthetic gel intended for application in open wounds prior to suturing in emergency departments.

4CT004
CategoryPediatric Pharmaceuticals
Description

Preservative-free intravenous formulation of melatonin for prevention and management of emergence delirium in children following general anaesthesia. Designed to stabilize sleep-wake cycle during post-operative recovery without causing deep sedation or respiratory depression.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1University Hospital of Copenhagen, Rigshospitalet
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-12
Description

Collaboration to advance CT004 (intravenous melatonin for emergence delirium) in children. Phase II study (MELA-PAED) of 676 children at five sites in Denmark initiated and funded by Rigshospitalet. Cessatech retains worldwide commercial rights to CT004. Jointly outlining regulatory strategy and final development plan.

cessatech.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-31
Description

US manufacturing partner for CT001. FDA registered outsourcing facility with strong sterile manufacturing capabilities and extensive nasal spray expertise. Collaborates with leading pediatric hospitals across the US. Successfully completed technology transfer and development batches with stability studies ongoing.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-08-26
Description

Exclusive agreement for commercialization of CT001 worldwide excluding US. Proveca is a global pharmaceutical company specializing in medicines for children. Holds marketing authorization and leads PUMA submission to EMA. Terms include upfront payment and double-digit royalties to Cessatech on net sales. Proveca also has non-exclusive option to license CT002 program.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-27
Description

Exclusive US co-development and commercialization royalty license agreement. Both parties share development costs and net profits equally (50/50). Market opportunity projected at $200-400 million within 5 years. Potential for revenues from 2024. Ventis focuses on innovative pain management therapies and distributes through early access program.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based specialty pharmaceutical company exclusively focused on paediatric medicines. Direct peer given its paediatric-only therapeutic focus and exclusive ex-US commercialisation partnership with Cessatech for CT001.

TypeDirect peer
Description

US specialty pharma that developed Valtoco, an intranasal diazepam spray for paediatric seizure rescue. Directly comparable as a small company commercialising a nasal-spray paediatric CNS drug through hospital and specialty channels.

TypeBroad incumbent
Description

Large established paediatric rare-disease biopharma. Comparable as a profitable, hospital-channel paediatric drug developer, though at vastly greater scale and with a broader portfolio than Cessatech's focused pipeline.

TypeBroad incumbent
Description

Swedish-headquartered specialty biopharma with a dedicated paediatric and rare-disease franchise distributed through hospital channels. Comparable European peer operating in adjacent paediatric specialty categories.

TypeBroad incumbent
Description

Acquired GW Pharmaceuticals and now markets paediatric neurology products (e.g., Epidiolex) through hospital and specialty pharmacy channels. Broad incumbent in paediatric neurology, an adjacent therapeutic area.

TypeEmerging player
Description

Danish specialty biopharma developing rare-disease endocrine therapies including paediatric endocrinology products. Comparable as a Danish paediatric-focused drug developer with hospital-administered products, and a connection to Cessatech's board (Flemming Steen Jensen, SVP).

TypeEmerging player
Description

Japan-based clinical-stage specialty pharma focused on neurology and rare diseases including paediatric indications. Comparable as a small-cap specialty pharma developing CNS therapies for hospital administration.

TypeBroad incumbent
Description

Specialty pharma division of Recordati operating in rare and paediatric diseases, distributing hospital-administered products globally. Comparable as a European-headquartered paediatric/rare-disease specialty commercial platform.

TypeBroad incumbent
Description

US specialty pharma commercialising CNS therapies including paediatric neurology assets. Comparable as a hospital- and specialty-channel CNS drug developer in adjacent paediatric indications.

TypeDirect peer
Description

French specialty pharma developing paediatric neurology and nephrology products for hospital use. Comparable as a small European paediatric specialty pharma operating in adjacent paediatric CNS/renal categories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cessatech

Pediatric Pharmaceuticalscessatech.com

Cessatech is a Danish pivotal-stage paediatric biotech company developing first-in-class fixed-dose nasal spray and injectable medicines for acute and emergency care in children. It licenses lead asset CT001 through exclusive US (Ventis/STAQ) and Europe/ex-US (Proveca) commercial partnerships ahead of near-term launches.

What Cessatech does

Cessatech A/S is a Danish pivotal-stage paediatric biotech company founded in 2020 as a spinout from Rigshospitalet, Copenhagen University Hospital. The company develops first-in-class specialty hospital medicines targeting acute and emergency care needs in children aged 1-17. Its portfolio addresses a documented under-treatment of pediatric pain where IV access is often painful or infeasible and where many current regimens rely on off-label use.

The lead asset, CT001 (Napatrin), is a fixed-dose combination nasal spray containing ketamine and sufentanil, leveraging a synergistic analgesic effect that enables approximately 30% opioid reduction without loss of efficacy. Pivotal trial 0205 enrolled 220 adult patients and final pediatric safety Study 0202 enrolled over 150 children, with top-line results showing 54% responder rate at 15 minutes and 88% at 30 minutes. The pipeline also includes CT002 (intranasal dexmedetomidine for procedural sedation, with EMA-approved PIP), CT003 (topical anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for post-anaesthesia emergence delirium, developed in collaboration with Rigshospitalet). CT001 has received a positive MDR opinion and an EMA PUMA-based MAA was submitted in August 2025.

Cessatech operates a capital-efficient, partnership-driven commercial model with a lean team of fewer than 10 employees. In the US, Ventis Pharma holds exclusive commercialization rights and STAQ Pharma is the manufacturing partner, with 50/50 cost and profit sharing and a projected $200-400M market opportunity within 5 years. In Europe and ex-US markets, Proveca Ltd holds exclusive commercialization rights and is the marketing authorization holder, with Cessatech receiving double-digit royalties plus upfront and milestone payments. The company is publicly listed on the Spotlight Stock Market under the ticker CESSA, having raised approximately DKK 78 million cumulatively since its oversubscribed 2020 IPO.

Cessatech firmographics

Firmographics
Name
Cessatech
Legal name
Cessatech A/S
Website
https://cessatech.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Cessatech is a Danish pivotal-stage paediatric biotech company developing first-in-class fixed-dose nasal spray and injectable medicines for acute and emergency care in children. It licenses lead asset CT001 through exclusive US (Ventis/STAQ) and Europe/ex-US (Proveca) commercial partnerships ahead of near-term launches.
Ownership category
akta.pro rank

Cessatech industry classification

Industry
Product category
Pediatric Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAM
First Aid & Wound Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Pediatric pharmaceuticals
  • Nasal spray medicines
  • Acute pain management
  • Fixed-dose combinations
  • Specialty hospital medicines

Where Cessatech is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Cessatech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Sales - US Market: Revenue from CT001 sales in the US market through the partnership with Ventis Pharma and STAQ Pharma. Both parties share development costs and net profits equally (50/50). Expected to generate revenue from 2024, though timeline has been extended due to manufacturing validation requirements.
  2. Licensing Royalties - Europe/Ex-US: Double-digit royalties to Cessatech on net sales in the licensed territory through the exclusive agreement with Proveca for worldwide commercialization excluding US. Proveca is the marketing authorization holder for Europe.
  3. Upfront and Milestone Payments: Upfront payment upon signature of the Proveca agreement plus potential milestone payments as regulatory and commercial milestones are achieved.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Cessatech product offering

Product offering

Core offering

Cessatech develops first-in-class specialty hospital medicines for children, focused on acute and emergency care. The lead product CT001 (Napatrin) is a fixed-dose combination analgesic nasal spray of ketamine and sufentanil for children aged 1-17 years experiencing acute pain. The pipeline also includes CT002 (procedural sedation nasal spray), CT003 (sterile local anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for emergence delirium).

Product overview

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children. The company's portfolio includes four pipeline products: CT001 (Napatrin) is the lead product, a nasal spray for acute pain in children aged 1-17; CT002 is a nasal spray for procedural sedation during MRI scans; CT003 is a topical anaesthetic gel for laceration repair; and CT004 is an intravenous melatonin formulation for emergence delirium. The company operates a capital-efficient, partnership-driven model with lead product CT001 advancing toward near-term commercialization in both US and European markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • CT001 (Napatrin) Fixed-dose analgesic nasal spray combining ketamine and sufentanil for acute pain relief in children aged 1-17 years. Non-invasive, needle-free formulation with fast onset, designed for children experiencing acute pain or pain related to medical procedures.
  • CT002 Non-invasive nasal spray containing dexmedetomidine for conscious sedation of children undergoing medical procedures such as MRI scans and diagnostic imaging.
  • CT003 Topical anaesthetic gel for paediatric laceration repair. Ready-to-use, sterile, needle-free local anaesthetic gel intended for application in open wounds prior to suturing in emergency departments.
  • CT004 Preservative-free intravenous formulation of melatonin for prevention and management of emergence delirium in children following general anaesthesia. Designed to stabilize sleep-wake cycle during post-operative recovery without causing deep sedation or respiratory depression.

Quantifiable outcome

  • 54% of patients reported pain relief (pain score ≤4/10) after 15 minutes
  • +4 more outcomes

Companies that use Cessatech

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Cessatech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cessatech partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • University Hospital of Copenhagen, RigshospitaletcoreStrategic or Co-development Partner · 12 June 2026Collaboration to advance CT004 (intravenous melatonin for emergence delirium) in children. Phase II study (MELA-PAED) of 676 children at five sites in Denmark initiated and funded by Rigshospitalet. Cessatech retains worldwide commercial rights to CT004. Jointly outlining regulatory strategy and final development plan.
  • STAQ PharmacoreChannel Partner/ Reseller/ Distributor · 31 October 2025US manufacturing partner for CT001. FDA registered outsourcing facility with strong sterile manufacturing capabilities and extensive nasal spray expertise. Collaborates with leading pediatric hospitals across the US. Successfully completed technology transfer and development batches with stability studies ongoing.
  • Proveca LtdcoreChannel Partner/ Reseller/ Distributor · 26 August 2024Exclusive agreement for commercialization of CT001 worldwide excluding US. Proveca is a global pharmaceutical company specializing in medicines for children. Holds marketing authorization and leads PUMA submission to EMA. Terms include upfront payment and double-digit royalties to Cessatech on net sales. Proveca also has non-exclusive option to license CT002 program.
  • Ventis Pharma CorporationcoreChannel Partner/ Reseller/ Distributor · 27 June 2023Exclusive US co-development and commercialization royalty license agreement. Both parties share development costs and net profits equally (50/50). Market opportunity projected at $200-400 million within 5 years. Potential for revenues from 2024. Ventis focuses on innovative pain management therapies and distributes through early access program.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Cessatech competitors and assessment

Company assessment

Direct peers

  • Proveca Ltd: UK-based specialty pharmaceutical company exclusively focused on paediatric medicines. Direct peer given its paediatric-only therapeutic focus and exclusive ex-US commercialisation partnership with Cessatech for CT001.
  • Neurelis Inc: US specialty pharma that developed Valtoco, an intranasal diazepam spray for paediatric seizure rescue. Directly comparable as a small company commercialising a nasal-spray paediatric CNS drug through hospital and specialty channels.
  • Advicenne: French specialty pharma developing paediatric neurology and nephrology products for hospital use. Comparable as a small European paediatric specialty pharma operating in adjacent paediatric CNS/renal categories.

Broad incumbents

  • BioMarin Pharmaceutical: Large established paediatric rare-disease biopharma. Comparable as a profitable, hospital-channel paediatric drug developer, though at vastly greater scale and with a broader portfolio than Cessatech's focused pipeline.
  • Swedish Orphan Biovitrum (Sobi): Swedish-headquartered specialty biopharma with a dedicated paediatric and rare-disease franchise distributed through hospital channels. Comparable European peer operating in adjacent paediatric specialty categories.
  • Jazz Pharmaceuticals: Acquired GW Pharmaceuticals and now markets paediatric neurology products (e.g., Epidiolex) through hospital and specialty pharmacy channels. Broad incumbent in paediatric neurology, an adjacent therapeutic area.
  • Recordati Rare Diseases: Specialty pharma division of Recordati operating in rare and paediatric diseases, distributing hospital-administered products globally. Comparable as a European-headquartered paediatric/rare-disease specialty commercial platform.
  • Acadia Pharmaceuticals: US specialty pharma commercialising CNS therapies including paediatric neurology assets. Comparable as a hospital- and specialty-channel CNS drug developer in adjacent paediatric indications.

Emerging players

  • Ascendis Pharma A/S: Danish specialty biopharma developing rare-disease endocrine therapies including paediatric endocrinology products. Comparable as a Danish paediatric-focused drug developer with hospital-administered products, and a connection to Cessatech's board (Flemming Steen Jensen, SVP).
  • Aculys Pharma: Japan-based clinical-stage specialty pharma focused on neurology and rare diseases including paediatric indications. Comparable as a small-cap specialty pharma developing CNS therapies for hospital administration.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Cessatech social profiles

Digital presence

Cessatech compliance and trust

Trust signal

Compliance2 records

Cessatech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cessatech leadership team

Management profile

Number of profiles

Profiles12 records

Cessatech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cessatech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cessatech

What does Cessatech do?

Cessatech develops first-in-class specialty hospital medicines for children, focused on acute and emergency care. The lead product CT001 (Napatrin) is a fixed-dose combination analgesic nasal spray of ketamine and sufentanil for children aged 1-17 years experiencing acute pain. The pipeline also includes CT002 (procedural sedation nasal spray), CT003 (sterile local anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for emergence delirium).

Is Cessatech a public or private company?

Cessatech is a private company. It is classified as public and is currently operating.

When was Cessatech founded?

Cessatech was founded in 2020. It employs 1 to 10 people.

Where is Cessatech based?

Cessatech is headquartered in Copenhagen, Denmark, in the Europe region.

How does Cessatech make money?

Three revenue lines are on record. Product Sales - US Market is the primary driver. The others are licensing Royalties - Europe/Ex-US and upfront and Milestone Payments.

Who are Cessatech's main competitors?

Direct peers on record are Proveca Ltd, Neurelis Inc and Advicenne. Broad incumbents are BioMarin Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals, Recordati Rare Diseases and Acadia Pharmaceuticals. Emerging players are Ascendis Pharma A/S and Aculys Pharma.

Does Cessatech have an API?

No public API is recorded for Cessatech.

What industry is Cessatech in?

Cessatech's product category is Pediatric Pharmaceuticals. Its primary akta.pro industry code is HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics), with a secondary code of HLAIADAM, First Aid & Wound Care. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comProveca and Cessatech plan next regulatory steps for KemSu following CHMP opinionThe EMA's CHMP maintained its negative opinion on the PUMA application for KemSu, a ketamine/sufentanil nasal spray for children's acute pain. Proveca and Cessatech will seek scientific advice to address remaining gaps and define a regulatory pathway for resubmission. The companies remain committed to making KemSu available to children needing new treatment options.news.cision.comCessatech – US commercial update for CT001Cessatech reported progress on its US commercialization of CT001 (sufentanil/ketamine nasal spray) two months after launch, having engaged about 50 hospital accounts. The company expects very limited sales in 2026 due to hospital review processes, with a strategic update planned later this year.MarketScreenerCessatech partner has released the first commercial batch of CT001 in the USCessatech's US manufacturing partner STAQ Pharma has released the first commercial batch of CT001, a nasal spray containing sufentanil and ketamine for children, according to a press release. The product is now available for delivery to the first US hospitals, allowing Cessatech and its partners to begin launch activities at selected hospitals. CEO Jes Trygved said establishing the product in the market will take time.news.cision.comCT001 ready for shipment to initial U.S. hospitals as launch activities commenceCessatech announced the release of CT001 by its U.S. partner STAQ Pharma, making the nasal spray available for shipment to initial U.S. hospitals. The first commercial batch marks an operational milestone, enabling launch activities with selected hospitals. The product targets acute moderate to severe pain in children aged 1-17.news.cision.comProveca intends to request a re-examination of CHMP opinion for CT001/KemSuThe EMA's CHMP adopted a negative opinion on Proveca's PUMA application for CT001/KemSu, a ketamine/sufentanil nasal spray for children's acute pain. Proveca plans to request a re-examination of the opinion, with the process expected to take several months.news.cision.comCessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in childrenCessatech announced a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance CT004, an intravenous melatonin formulation for post-anaesthesia delirium in children. A phase II trial of 676 children at five Danish sites was initiated in 2025, and Cessatech retains worldwide commercial rights. The company will focus on CT002 and CT004 going forward.news.cision.comFirst Quarter Report Q1-2026Cessatech reported Q1 2026 interim results with net revenue of KDKK 0 and a net loss of KDKK 3.228. The company advanced CT001, with EMA regulatory review progressing after MAA submission, and presented clinical data from Study 0202 at SPPM. The US launch timeline was extended pending final manufacturing validation.news.cision.comMinutes from the Annual General Meeting in Cessatech A/SCessatech A/S held its Annual General Meeting on March 30, 2026 in Hellerup, Denmark, where shareholders approved all agenda items including the audited Annual Report for 2025 and re-elected the Board of Directors and auditor. The company reported a consolidated loss of tDKK 10,904 for 2025, which will be carried forward to the next financial year. The Board subsequently elected Martin Olin as Chairman of the Board following the meeting.news.cision.comWelcome to the first quarter of 2026Cessatech, a Danish pediatric biotech company, issued a first-quarter 2026 shareholder update reviewing 2025 progress and outlining plans for its lead product CT001, a pediatric acute pain treatment. Key regulatory milestones include a positive MDR opinion received and a Marketing Authorisation Application submitted to the European Medicines Agency, while US launch preparations are advancing with manufacturing partner STAQ Pharma completing development batches and stability studies underway. The company also announced new CT001 patents secured in the US and Asia-Pacific, and a new Senior Director of Finance & Investor Relations hired in November 2025.news.cision.comThird Quarter Report Q3-2025Cessatech A/S, a Danish pharmaceutical company developing paediatric medicines, released its Q3 2025 results showing net revenue of KDKK 1.243 and a net loss of KDKK -3.050, with cash reserves of KDKK 9.090. The company announced the closure of clinical and regulatory activities for its lead asset CT001 (a paediatric acute pain nasal spray) and completed the US manufacturing technology transfer in October. Cessatech is now focused on launch and supply planning with commercial partners as it advances toward upcoming US market activities.